Last reviewed · How we verify
GHB04L1
At a glance
| Generic name | GHB04L1 |
|---|---|
| Also known as | A/Vietnam/1203/04 (H5N1)-ΔNS1 virus reassortant |
| Sponsor | AVIR Green Hills Biotechnology AG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults (PHASE1)
- Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GHB04L1 CI brief — competitive landscape report
- GHB04L1 updates RSS · CI watch RSS
- AVIR Green Hills Biotechnology AG portfolio CI